Myasthenia gravis (MG) is an antibody-mediated autoimmune disease of the neuromuscular junction. In approximately 80% of patients, auto-antibodies to the muscle nicotinic acetylcholine receptor ...

The new report suggests patients with acetylcholine receptor (AChR) antibody titers above 8.11 nmol/L were at higher risk of conversion.

The weakness in myasthenia gravis (MG) is mediated by autoantibodies against adult muscle acetylcholine receptors (AChR) at the neuromuscular junction; most of these antibodies also bind to fetal ...

When acetylcholine binds to its receptor at the neuromuscular junction, it leads to activation of the receptor and a contraction of the muscle. In myasthenia gravis, the body’s immune system ...

More than 60% of complement inhibitor–naive patients with acetylcholine receptor–positive generalized myasthenia gravis (MG) in diverse clinical populations had a clinically meaningful ...